The EMA And EU Expansion - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe
The EMA And EU Expansion
In addition to coordinating centralised authorisation procedures for medicines, the EMA is responsible for a number of other tasks, and must rely heavily on the involvement of the EU member states and the countries of the European Economic Area. The greatest challenge faced by the agency, however, is the continuing expansion of the EU.
Jun 1, 2011
By: Nathan Jessop
Pharmaceutical Technology Europe
Volume 23, Issue 6
« Previous
123

References

1. Europa, "The 2004 enlargement: the challenge of a 25-member EU", Europa website 2007. http://europa.eu/ (accessed 12 May 2011)

2. I. Eckhart, "The European Medicines Agency (EMEA) — from Research to Therapies", Bridges 11 2006. http://www.ostina.org/ (accessed 12 May 2011)

3. EMA, "European Union enlargement. EMA", EMA website 2011. http://www.ema.europa.eu/ (accessed 12 May 2011)

4. Anon., "EMEA in the European system", Bull. Soc. Sci. Med. 1/2004, 87–92 (2004).

5. IDABC, "EUDRANET: European Telecommunication Network in Pharmaceuticals (EMEA)", Europa website 2004. http://ec.europa.eu/ (accessed 12 May 2011)

6. EMA, "EU Regulatory Network - Challenges and Opportunities for Croatia", EMA website 2008. http://www.emea.europa.eu/htms/euenlargement (accessed 12 May 2011)

7. EMA, "Successful Rijeka conference strengthens EU-Croatian cooperation on medicines regulation", EMA website 2008. http://www.ema.europa.eu/ (accessed 12 May 2011)

8. H. Prange, Queen's Papers on Europeanisation No 8/2002 (2002). http://www.qub.ac.uk92/ (accessed 12 May 2011).

« Previous
123

ADVERTISEMENT

blog comments powered by Disqus
About the Author

Nathan Jessop

Nathan Jessop is a columnist for Pharmaceutical Technology Europe. Articles by Nathan Jessop
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
20%
To all process for new products only
13%
To select process for new products only
24%
To select processes for both new and legacy products
20%
Do not use QbD
22%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>
Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Inadequate Access to Medicines Puts EU at Risk
FDA Offers Insight on QbD for Modified-Release Products
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
FindPharma Custom Search
Featured Jobs

More Jobs
Source: Pharmaceutical Technology Europe, 6/1/2011
 Click here